Operating Lease, Right-of-Use Asset in USD of Lineage Cell Therapeutics, Inc. from Q1 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Lineage Cell Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and change rate from Q1 2019 to Q3 2025.
  • Lineage Cell Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2025 was $2.31M, a 2.16% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Lineage Cell Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed
Q3 2025 $2.31M -$51K -2.16% Sep 30, 2025 10-Q 2025-11-06
Q2 2025 $1.82M -$767K -29.7% Jun 30, 2025 10-Q 2025-08-12
Q1 2025 $1.9M -$951K -33.3% Mar 31, 2025 10-Q 2025-05-13
Q4 2024 $2.14M -$378K -15% Dec 31, 2024 10-Q 2025-11-06
Q3 2024 $2.36M Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $2.58M Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $2.86M Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $2.52M Dec 31, 2023 10-K 2025-03-10
Q4 2020 $215K -$560K -72.3% Dec 31, 2020 10-K 2021-03-11
Q4 2019 $775K Dec 31, 2019 10-K 2021-03-11
Q3 2019 $4.95M Sep 30, 2019 10-Q 2019-11-12
Q2 2019 $4.55M Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $4.68M Mar 31, 2019 10-Q 2019-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.